Our Pricing

Find the Cheapest Wegovy Prices for Weight Loss at Cured Pharmacy

Published on: June 03, 2026

Searching for the cheapest Wegovy prices UK online pharmacies offer? At Cured Pharmacy, we provide genuine UK-licensed Wegovy (semaglutide) from £79.00, with transparent upfront pricing shown before your free online consultation. Our UK-registered clinical team ensures you receive safe, effective weight management treatment at the lowest guaranteed prices in the UK.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight alongside related health conditions [1]. Semaglutide mimics a natural hormone that regulates appetite and food intake by acting on areas of the brain that control hunger signals.

In the landmark STEP 1 clinical trial, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. The medication works by slowing gastric emptying, reducing appetite, and helping patients feel fuller for longer periods after eating.

Wegovy is administered as a once-weekly subcutaneous injection, starting at a low dose of 0.25mg and gradually increasing over 16-20 weeks to the maintenance dose of 2.4mg weekly [2]. This dose escalation approach, overseen by your UK prescriber, helps minimise gastrointestinal side effects whilst your body adjusts to the medication.

Wegovy Pricing Structure at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00 per pen, with the final cost determined by your prescribed dose following clinical assessment. We guarantee the lowest prices in the UK market, with transparent pricing displayed before you begin your free online consultation.

Your initial prescription typically covers a four-week supply, with the dose titration schedule requiring different strengths during the first months of treatment. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team ensure you receive the correct dosing progression as outlined in the MHRA-approved prescribing information [2].

Unlike some providers, we never hide costs behind lengthy consultations. You'll see exactly what you'll pay before speaking with a prescriber, and there are no hidden fees for the clinical assessment, which takes under three minutes to complete online.

Understanding Wegovy Dose Escalation Costs

The dose escalation schedule means your monthly cost will vary during the first 16-20 weeks as you progress through 0.25mg, 0.5mg, 1mg, 1.7mg, and finally 2.4mg doses. Your UK prescriber will provide a clear breakdown of expected costs throughout your treatment journey, ensuring no surprises.

Clinical Evidence Behind Wegovy's Effectiveness

The STEP clinical trial programme, comprising five major randomised controlled trials with over 4,500 participants, established semaglutide 2.4mg as one of the most effective pharmacological weight loss treatments available [1][3]. STEP 1 demonstrated that 86.4% of participants achieved at least 5% weight loss, whilst 69.1% achieved at least 10% reduction [1].

STEP 2 specifically examined patients with type 2 diabetes, showing an average weight reduction of 9.6% compared to 3.4% with placebo over 68 weeks [3]. These results led to NICE guidance recommending semaglutide for weight management in specific patient populations when prescribed alongside a reduced-calorie diet and increased physical activity.

Long-term data from STEP 4 revealed that participants who continued Wegovy maintained their weight loss, whilst those switched to placebo regained a significant portion of lost weight [3]. This underscores the importance of ongoing treatment and lifestyle modification for sustained weight management outcomes.

Real-World Outcomes in UK Clinical Practice

Since Wegovy's UK launch, real-world evidence has supported the clinical trial findings. Our clinical team at Cured Pharmacy has observed that patients who adhere to the prescribed regimen and implement dietary changes typically experience meaningful weight reduction within the first 12-16 weeks of treatment, subject to individual response and medical factors.

Comparing Wegovy to Other Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms of action and clinical profiles. Wegovy represents the current gold standard for GLP-1 receptor agonist therapy, though newer dual-action treatments have emerged with potentially greater efficacy in clinical trials.

Saxenda, containing liraglutide (an earlier GLP-1 agonist), requires daily injections and demonstrated average weight loss of 8% in clinical trials — lower than Wegovy's 14.9% average [1][4]. Oral medications like Mysimba work through different pathways affecting appetite and reward centres, whilst Orlistat reduces fat absorption in the digestive system.

Your choice of treatment depends on multiple factors including your medical history, BMI, comorbidities, injection preference, and cost considerations. A UK prescriber will assess which option aligns best with your clinical profile during your online consultation at Cured Pharmacy.

Who Can Use Wegovy in the UK

Wegovy is licensed in the UK for adults with a BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [2]. The medication must be prescribed alongside a reduced-calorie diet and increased physical activity programme.

Certain medical conditions preclude Wegovy use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, or diabetic retinopathy [2]. Your UK prescriber will review your complete medical history to determine suitability.

Wegovy is not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment. If you're taking other medications, particularly insulin or sulfonylureas, dose adjustments may be necessary to prevent hypoglycaemia.

Assessment Process at Cured Pharmacy

Our online clinical assessment takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications. A UK-registered prescriber reviews your responses and determines whether Wegovy is clinically appropriate for you. If approved, your prescription is sent directly to our GPhC-registered pharmacy (9012511) for dispensing and discreet delivery.

Starting Wegovy: What to Expect

Most patients begin noticing appetite reduction within the first week of Wegovy treatment, though significant weight loss typically becomes apparent after 8-12 weeks as you progress through dose escalation [1]. The medication is most effective when combined with a structured nutrition plan reducing daily caloric intake by 500-1000 calories and regular physical activity.

Common side effects include nausea, diarrhoea, vomiting, constipation, and abdominal pain, particularly during dose increases [2]. These gastrointestinal effects are usually mild to moderate and diminish as your body adjusts. Taking the injection on the same day each week and staying well-hydrated can help manage these symptoms.

Your UK prescriber may recommend stopping treatment if you haven't achieved at least 5% weight loss after 12-16 weeks at the maintenance dose, as continued use may not provide sufficient benefit [2]. Regular follow-up ensures your treatment remains safe and effective throughout your weight management journey.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., ... & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and are not guaranteed.